Introduction
============

Differentiated thyroid carcinoma (DTC), which mainly includes cancers of papillary and follicular histologies, is the most common form of thyroid cancer ([@b1-ol-0-0-10088]) DTC typically has a favorable prognosis, with an overall 10-year survival rate above 90%. As reported by epidemiological studies, the incidence of thyroid cancer has been on the increase in previous decades ([@b2-ol-0-0-10088]). The vast majority (87%) of thyroid cancers detected in the last 15 years were diagnosed as small DTC (sDTC), which is defined as tumors ≤2 cm in their largest diameter ([@b3-ol-0-0-10088],[@b4-ol-0-0-10088]). Thus, defining the appropriate treatment and management strategies for patients with early stage DTC, especially sDTC, is necessary.

In the 6th edition of the Union for International Cancer Control (UICC)/American Joint Committee on Cancer (AJCC) ([@b5-ol-0-0-10088]--[@b7-ol-0-0-10088]), the tumor, node, metastases (TNM) staging system defined intrathyroidal tumors, with the largest diameter being ≤2 cm, as T1. Previous findings have suggested that tumors \>1 cm have a worse prognosis ([@b8-ol-0-0-10088]). Thus, the 7th AJCC TNM staging system made a subdivision of T1 tumors into T1a (≤1 cm) and T1b (1--2 cm) ([@b9-ol-0-0-10088]). Furthermore, the 8th AJCC TNM staging system continued to use T1a/T1b ([@b10-ol-0-0-10088]). The 2015 American Thyroid Association guidelines recommended different therapeutic management for the two DTC subgroups ([@b11-ol-0-0-10088]). However, in other studies it was emphasized that smaller DTCs did not indicate better prognosis, and that there was no difference between the two subgroups ([@b12-ol-0-0-10088]--[@b14-ol-0-0-10088]). Due to the inconsistent conclusions of the previous respective studies and a lack of prospective studies, whether it is clinically beneficial to subdivide sDTCs remains controversial.

The aim of the present study was to investigate whether the subgroups (group *S1*, defined as tumors ≤1 cm and group *S2*, defined as tumors \>1 cm and ≤2 cm) are distinguishable based on patient prognosis.

Materials and methods
=====================

### Search strategy and study selection

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) was referred in the process of our meta-analysis ([@b15-ol-0-0-10088]). A comprehensive literature search for studies published before September 2018 was performed in the PubMed and Web of Science databases. We used the following keywords as the search algorithm: ('differentiated thyroid carcinoma' OR 'DTC') AND ('follow up' OR 'result' OR 'prognosis' OR 'death' OR 'recurrence') AND ('tumor size' OR 'T1') AND 'patients'. All of the reference lists from the main articles were inspected for additional eligible studies.

Studies were considered eligible if they met the following inclusion criteria: i) The original publication was in English; ii) all enrolled patients received surgery without other forms of treatments (including radiotherapy, chemotherapy and targeted therapy); iii) studies were about primary tumors; iv) baseline characteristics of enrolled patients were described in detail (including sex, age, and treatment); v) studies provided information regarding recurrence and death events in relation to clinicopathological factors of the patients.

First, abstracts of all identified citations were screened, and those not meeting the inclusion criteria were excluded. Subsequently, the full texts of the remaining articles were rescreened, and studies were excluded if they met the following exclusion criteria: i) Small sample size (≤20); ii) studies lacking prognosis or recurrence data classified by tumor size; iii) articles that only offered the relative information of one group; iv) tumor sizes were measured using imaging data, instead of in surgery or pathological specimen.

### Data extraction and quality assessment

According to the inclusion/exclusion criteria, 21 studies were included in the current meta-analysis. We extracted the following data from each study: the first author\'s name, year of publication, study location, number of patients included, study design, period of follow-up, sex composition, therapeutic method, and odds ratios (ORs) with their 95% confidence intervals (95% CIs), resulting from univariate analysis (either published or derived from reported data).

Study quality was scored using the Newcastle-Ottawa Scale (NOS) ([@b16-ol-0-0-10088]). The NOS is frequently used for non-random studies, such as cohort studies. The maximum score for a cohort study was 9, and studies scoring between 5 and 9 are generally considered high quality. The quality scores of the 21 studies ranged from 7 to 9, and all were considered adequate for inclusion in the meta-analysis.

### Ethics approval

The present study was approved by the Human Ethics Committee/Institutional Review Board of Fudan University Shanghai Cancer Center (Shanghai, China).

### Statistical analysis

The meta-analysis was performed using STATA version 12.0 program (StataCorp, College Station, TX, USA) to facilitate the pooling of results across studies. The final results are expressed as an OR (odds ratio) and its 95% confidence interval (CI). Heterogeneity in each study was assessed using χ^2^ tests (Q-value and *P*-value) and I^2^ measures. Significant heterogeneity was defined as a χ^2^ test with *P*\<0.05 or I^2^ \>50%. Random-effect models (Mantel-Haenszel and Der Simonnian-Laird methods) were then used for primary analyses in datasets with significant heterogeneity. Primary datasets without significant heterogeneity were analyzed using fixed-effect models (Mantel-Haenszel method). If there was significant heterogeneity and \>10 studies included, we accounted for statistical heterogeneity by meta-regression analysis. Publication biases were assessed by Begg\'s test in each meta-analysis, and we assumed publication bias was present if *P*\<0.05.

Results
=======

### Baseline study and patient characteristics

The process of selecting studies according to the inclusion/exclusion criteria is shown in [Fig. 1](#f1-ol-0-0-10088){ref-type="fig"}, whereby 21 studies were included in the final meta-analysis ([@b5-ol-0-0-10088]--[@b8-ol-0-0-10088], [@b12-ol-0-0-10088]--[@b14-ol-0-0-10088], [@b17-ol-0-0-10088]--[@b30-ol-0-0-10088]). The principal characteristics of the 21 studies are shown in [Table I](#tI-ol-0-0-10088){ref-type="table"}. In total 219,291 patients were involved, and the mean age of the enrolled patients in each study was similar. All 21 studies were retrospective cohort studies published between 2004 and 2017, except one prospective study. The follow-up time ranged from 3.6 to 14.1 years. The main treatment was total thyroidectomy (TT) or near total thyroidectomy (nTT) with postoperative radioiodine as selective adjuvant therapy.

All the NOS scores of the eligible studies were greater than 5 for the 9 questions, with an average of 8.05 (range, 7--9), indicating good quality for meta-analysis. The included studies were all cohort studies with definitive controls for selection, yielding the good scores.

### Association between tumor size and recurrence in DTC

As shown in [Fig. 2A](#f2-ol-0-0-10088){ref-type="fig"}, the risk of recurrence for DTC patients based on tumor size was compared in 10 studies ([@b6-ol-0-0-10088],[@b8-ol-0-0-10088],[@b12-ol-0-0-10088]--[@b14-ol-0-0-10088],[@b17-ol-0-0-10088],[@b21-ol-0-0-10088],[@b23-ol-0-0-10088],[@b26-ol-0-0-10088]--[@b27-ol-0-0-10088]). In the meta-analysis, larger tumor size (*S2 vs. S1*) was associated with higher risk of postoperative recurrence in sDTC patients (OR=1.575; 95% CI=1.428--1.738; *P\<*0.05). No significant statistical heterogeneity was detected among these studies (*P*=0.653; I^2^=0.0%).

The prognostic influence of tumor size is partly attributable to its association with more aggressive histologic features such as extrathyroidal extension (ETE), rather than the impact of size itself. Thus, our analysis compared the influence of T1a and T1b on recurrence based on the data from four studies ([@b12-ol-0-0-10088]--[@b14-ol-0-0-10088],[@b17-ol-0-0-10088]). In the meta-analysis, T1b also indicated higher risk of recurrence than T1a (OR=1.520; 95% CI=1.072--2.155; *P*\<0.05) ([Fig. 2B](#f2-ol-0-0-10088){ref-type="fig"}). There was no significant statistical heterogeneity among these studies (*P*=0.168, I^2^=40.6%).

### Association between tumor size and survival in DTC

Eleven articles provided survival data for groups *S1* and *S2* ([@b5-ol-0-0-10088]--[@b8-ol-0-0-10088],[@b12-ol-0-0-10088],[@b17-ol-0-0-10088],[@b18-ol-0-0-10088],[@b21-ol-0-0-10088],[@b23-ol-0-0-10088],[@b25-ol-0-0-10088],[@b27-ol-0-0-10088]). Due to the favorable prognosis of DTC, there was no end-point mortality data in 5 studies. Based on the random-effect meta-analysis, tumor size (*S1 vs. S2*) had no association with survival in DTC patients (OR=1.160, 95% CI=0.810--1.662; *P*=0.448) ([Fig. 3A](#f3-ol-0-0-10088){ref-type="fig"}). However, significant statistical heterogeneity was detected among these studies (*P*\<0.05, I^2^=75.8%). Thus, a meta-regression analysis was performed to explore the sources of heterogeneity. Study location (*P*=0.49), cohort size (*P*=0.286), follow-up period (*P*=0.282), patient age (*P*=0.131) and sex composition (*P*=0.866) were not the sources of heterogeneity. However, the year of publication potentially caused statistical heterogeneity (*P*\<0.05). Subgroup analysis of the nine studies published after 2009 ([@b5-ol-0-0-10088]--[@b7-ol-0-0-10088],[@b12-ol-0-0-10088],[@b17-ol-0-0-10088],[@b21-ol-0-0-10088],[@b23-ol-0-0-10088],[@b25-ol-0-0-10088],[@b27-ol-0-0-10088]) indicated group *S2* had a worse prognosis compared with *S1* (OR=1.498, 95%CI=1.357--1.653; *P*\<0.05). However, an analysis of the two studies conducted prior to 2009 showed the opposite conclusion (OR=0.800; 95% CI=0.670--0.955; *P*\<0.05) ([@b8-ol-0-0-10088],[@b18-ol-0-0-10088]) ([Table II](#tII-ol-0-0-10088){ref-type="table"}; [Fig. 4](#f4-ol-0-0-10088){ref-type="fig"}). There was no significant statistical heterogeneity among the studies when divided by publication date (before 2009, *P*=0.714, I^2^=0.0%; after 2009, *P*=0.826, I^2^=0.0%).

Aggressive histological features can also affect prognosis; therefore, T stage was analyzed independently to determine whether T1b impacted postoperative survival compared with T1a. The meta-analysis of the data from three studies ([@b7-ol-0-0-10088],[@b12-ol-0-0-10088],[@b25-ol-0-0-10088]) revealed that T1b indicated a worse prognosis compared with T1a (OR=1.504, 95% CI=1.353--1.672; *P*\<0.05) ([Fig. 3B](#f3-ol-0-0-10088){ref-type="fig"}). No statistical heterogeneity (*P*=0.775, I^2^=0.0%) was detected.

### Association between tumor size and prognosis in PTC

Considering that different histologies (papillary thyroid, follicular thyroid and Hürthle cell cancer) indicate different prognoses, we independently analyzed the influence of the two groups (*S1* vs. *S2*) on the prognosis of PTC patients. The meta-analysis based on four studies ([@b8-ol-0-0-10088],[@b12-ol-0-0-10088],[@b17-ol-0-0-10088],[@b23-ol-0-0-10088]) revealed that larger tumor size (*S2*) increased the risk of recurrence for sPTC patients compared with *S1* (OR=1.580, 95% CI=1.430--1.747; *P*\<0.05), and there was no statistical heterogeneity between these studies (*P*=0.337, I^2^=3.0%) ([Fig. 5A](#f5-ol-0-0-10088){ref-type="fig"}). Due to the significant heterogeneity (*P*=0.015, I^2^=62.1%), the random effect model was used for the remaining seven studies ([@b5-ol-0-0-10088],[@b8-ol-0-0-10088],[@b12-ol-0-0-10088],[@b17-ol-0-0-10088],[@b18-ol-0-0-10088],[@b23-ol-0-0-10088],[@b25-ol-0-0-10088]) to explore the subgroup effect on survival. The analysis revealed that there was no statistical difference between the two groups (*S2 vs. S1*) in survival (OR=1.101, 95% CI=0.708--1.712; *P*=0.668) ([Fig. 5B](#f5-ol-0-0-10088){ref-type="fig"}).

### Tumor size and aggressive histologic features in DTC

The relationship between tumor size and aggressive histological features was also analyzed. Multifocality, ETE, bilaterality, vascular invasion, lymph node metastases and distant metastases were compared in eight ([@b12-ol-0-0-10088]--[@b14-ol-0-0-10088],[@b18-ol-0-0-10088],[@b19-ol-0-0-10088],[@b24-ol-0-0-10088],[@b25-ol-0-0-10088],[@b28-ol-0-0-10088]), five ([@b14-ol-0-0-10088],[@b18-ol-0-0-10088],[@b19-ol-0-0-10088],[@b22-ol-0-0-10088],[@b27-ol-0-0-10088]), three ([@b12-ol-0-0-10088],[@b18-ol-0-0-10088],[@b28-ol-0-0-10088]), four ([@b7-ol-0-0-10088],[@b12-ol-0-0-10088],[@b13-ol-0-0-10088],[@b18-ol-0-0-10088]), eleven ([@b6-ol-0-0-10088],[@b7-ol-0-0-10088],[@b12-ol-0-0-10088],[@b14-ol-0-0-10088],[@b18-ol-0-0-10088]--[@b20-ol-0-0-10088],[@b24-ol-0-0-10088],[@b28-ol-0-0-10088]--[@b30-ol-0-0-10088]) and five ([@b7-ol-0-0-10088],[@b12-ol-0-0-10088],[@b14-ol-0-0-10088],[@b18-ol-0-0-10088],[@b24-ol-0-0-10088]) studies, respectively. Based on the meta-analysis, *S2* was found to be associated with aggressive histological features more often compared with *S1*, including ETE (OR=2.575, 95% CI=1.603--4.135; *P*\<0.05) ([Fig. 6A](#f6-ol-0-0-10088){ref-type="fig"}), bilaterality (OR=2.278, 95% CI=1.905--2.723; *P*\<0.05) ([Fig. 6B](#f6-ol-0-0-10088){ref-type="fig"}), vascular invasion (OR=4.494, 95% CI=2.812--7.183, *P*\<0.05) ([Fig. 6C](#f6-ol-0-0-10088){ref-type="fig"}), lymph node metastases (OR=1.12, 95% CI=1.10--1.14, *P*\<0.05) ([Fig. 6E](#f6-ol-0-0-10088){ref-type="fig"}) and distant metastases (OR=1.373, 95% CI=1.155--1.631; *P*\<0.05) ([Fig. 6D](#f6-ol-0-0-10088){ref-type="fig"}). Although it has been reported that tumors \>1 cm are more frequently associated with multifocality than tumors ≤1 cm, no significant association was found in our meta-analysis (OR=1.242, 95% CI 0.899--1.716; *P*=0.188) ([Fig. 6F](#f6-ol-0-0-10088){ref-type="fig"}). There was no statistical heterogeneity among these studies when evaluating the association with bilaterality (*P*=0.632, *I*^2^=0.0%), lymph node metastases (*P*=0.146, I^2^=31.6%), and distant metastases (*P*=0.717, *I*^2^=0.0%). However, significant statistical heterogeneity was detected among the studies predicting correlations between tumor size and multifocality (*P*\<0.05, I^2^=80.9%), extrathyroidal extension (*P*\<0.05, I^2^=75.6%) and vascular invasion (*P*\<0.05, I^2^=75.3%). Furthermore, Begg\'s test was negative for all analyses.

Discussion
==========

Primary tumor diameter has been described as a determinant for outcome in DTC ([@b9-ol-0-0-10088]). The subdivision of sDTC is based on previous studies that indicated tumors \>1 cm had worse prognoses ([@b8-ol-0-0-10088]). However, it remains controversial whether the subgroups (*S1 vs. S2*) influence the prognosis of sDTC and what the appropriate therapeutic strategies are for patients in each subgroup. Thus, we determined whether tumor size \>1 cm would impact recurrence and survival in sDTC. The results of our study offer some guidelines for physicians dealing with sDTC patients.

The current meta-analysis focused on the effects of tumor size (*S2 vs. S1*) on postoperative recurrence and survival. The results indicated that patients with *S2* had a higher risk of postoperative recurrence compared with *S1* during follow-up. However, there was no statistical difference in survival between patients within the groups, and significant statistical heterogeneity was detected during analysis. Based on meta-regression analysis, publication year potentially caused the statistical heterogeneity (*P*\<0.05). In the subgroup meta-analysis, the subgroup including nine studies published after 2009 showed that *S2* was associated with worse prognoses compared with *S1*, but the subgroup of two studies published before 2009 showed the opposite; there were no statistical heterogeneities in either subgroup. Of note, the 7th AJCC\'s TNM staging guide was published in 2009, which subdivided T1 to T1a and T1b ([@b9-ol-0-0-10088]). This subdivision may heighten differences between the two subgroups. Further prospective studies are necessary to confirm the influence of tumor size on survival in sDTC.

To remove the effects of aggressive histological features such as ETE, we analyzed the influence of T stage (T1a *vs*. T1b) independently on postoperative prognosis. The results also showed that T1b increased the risk of recurrence and death compared with T1a. Since different pathological patterns of DTC indicate different prognoses, we analyzed the two groups (*S1 vs. S2*) in PTC independently. The meta-analysis revealed that *S2* increased the risk of recurrence for sPTC patients compared with *S1*, but there was no statistical difference between the two groups on survival. Given that the prognostic influence of tumor size is partly due to its association with aggressive histological features, our study explored the correlation between tumor size and other clinicopathological factors. The results confirmed that *S2* sDTC was more often associated with ETE, bilaterality, vascular invasion, lymph node metastases and distant metastases than *S1*.

The optimal treatment for the patients with sDTC is controversial. Bilimoria *et al* ([@b8-ol-0-0-10088]) reported a retrospective study enrolling 52,173 papillary thyroid carcinoma patients (including 28,016 sPTC patients) that concluded lobectomy as initial treatment was inadequate and had a worse prognosis regarding recurrence and death events compared with total thyroidectomy for the patients with *S2* disease (for recurrence: HR=1.24, 95% CI=1.01--1.65, *P*=0.04; for survival: HR=1.49, 95% CI=1.02--2.17, *P*=0.04), but for patients with *S1* disease, the two surgical approaches made no difference in prognosis. However, the 2015 ATA guidelines also recommended that thyroid lobectomy alone may be sufficient initial treatment for low-risk DTC ≤4 cm, unless there are clear indications to remove the contralateral lobe ([@b11-ol-0-0-10088]) Momesso *et al* ([@b26-ol-0-0-10088]) retrospectively analyzed clinical data from 176 DTC patients and argued that the surgical approach (total thyroidectomy or subtotal thyroidectomy) did not influence postoperative survival or recurrence for patients in either group; they also found no influence from radioiodine therapy. Ito *et al* ([@b17-ol-0-0-10088]) investigated the prognosis of 2,638 patients with T1N0M0 papillary thyroid carcinoma (PTC) who underwent initial surgery without radioiodine therapy. Those authors concluded that total thyroidectomy is not mandatory for T1N0M0 PTC patients unless other diseases coexisted requiring total thyroidectomy if a 1% risk of recurrence to the remnant thyroid is acceptable, and radioiodine ablation therapy is also not necessary. Based on a retrospective study of 1522 T1N0M0 DTC patients, Wang *et al* ([@b13-ol-0-0-10088]) found no difference in disease-specific survival among 1,522 patients with T1 tumors, and there was no difference in the risk of recurrence between total thyroidectomy and less than total thyroidectomy both for the patients with T1a and T1b (T1a: P=0.105; T1b: P=0.868).

The major limitation of this meta-analysis was that only 21 studies were suitable based on the inclusion and exclusion criteria. Although 358 articles were identified, most of the studies did not offer sufficient statistics about recurrence or survival subdivided among patients with *S1* and *S2* disease. There were few studies with the specific aim of investigating the effect of tumor size on patient prognosis. Thus, large-scale prospective studies are required to confirm the influence of tumor size on prognosis in sDTC. Moreover, since there were few data regarding the association between pathological type and subgroup (*S1* and *S2*), we could not adequately perform analyses on these factors. The limitation of insufficient availability of studies included resulted in some findings being heavily weighed by these few studies. Finally, publication bias is a major concern in all forms of pooled analyses, while our analysis revealed that this was not a complicating variable for any of the included studies.

Our meta-analysis suggested that patients with *S2* have an increased risk of postoperative recurrence and mortality compared with *S1* patients, and comparisons between T1a and T1b came to the same conclusions. Furthermore, the meta-analysis indicated that *S2* sDTC was more commonly associated with ETE, bilaterality, vascular invasion, lymph node metastases and distant metastases compared with *S1*. In summary, our analysis suggests that it is necessary to subdivide sDTC into *S1* and *S2* subgroups due to their different effects on prognosis, especially recurrence. Future prospective studies are required to confirm the influence of tumor size on prognosis in sDTC.
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![The OR for the association between tumor size and survival in sDTC is shown with 95% CIs. (A) Comparison between group S2 vs. S1 using the random effects model, and (B) T1b and T1a using the fixed effects model. CI, confidence interval; OR, odds ratio; sDTC, small-differentiated thyroid carcinoma.](ol-17-05-4229-g02){#f3-ol-0-0-10088}
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![Meta-analysis results regarding the association between subgroups (S2 vs. S1) and prognosis in sPTC are shown as the ORs with 95% CIs. (A) The fixed effects model comparing recurrence between subgroups. (B) The random effects model comparing survival between subgroups. CI, confidence interval; OR, odds ratio; sDTC, small-differentiated thyroid carcinoma.](ol-17-05-4229-g04){#f5-ol-0-0-10088}

![Associations with aggressive histologic features between subgroups (S2 vs. S1) are shown as the OR with 95% CIs. (A) The random effects model for the association with ETE. (B) The fixed effects model for the correlation with bilaterality. (C) The random effects model for the correlation with vascular invasion. (D) The fixed effects model for the correlation with distant metastases. (E) The fixed effects model for the correlation with lymph node metastases. (F) The random effects model for the correlation with multifocality. CI, confidence interval; OR, odds ratio; sDTC, small-differentiated thyroid carcinoma; ETE, extrathyroidal extension.](ol-17-05-4229-g05){#f6-ol-0-0-10088}

###### 

Baseline characteristics of the studies included.

  First author   Region            Year   Sample    Histology   Study^[a](#tfn1-ol-0-0-10088){ref-type="table-fn"}^   Follow-up (years)   Mean age (years)   Surgery^[b](#tfn2-ol-0-0-10088){ref-type="table-fn"}^   RAI         Quality score   (Refs.)
  -------------- ----------------- ------ --------- ----------- ----------------------------------------------------- ------------------- ------------------ ------------------------------------------------------- ----------- --------------- -----------------------
  Pellegriti     Italy             2004   299       PTC         R                                                     3.8                 41.9               nTT,TT                                                  30.40%      9               ([@b18-ol-0-0-10088])
  Barbaro        Italy             2005   91        PTC         R                                                     None                No detail          TT                                                      No detail   7               ([@b19-ol-0-0-10088])
  Reddy          USA               2006   551       DTC         R                                                     3.6                 No detail          TT or sTT                                               No detail   7               ([@b20-ol-0-0-10088])
  Bilimoria      USA               2007   28,016    PTC         R                                                     5.8                 43                 TT,lobectomy                                            51.30%      7               ([@b8-ol-0-0-10088])
  Rossi          Italy             2008   426       DTC         R                                                     5.4                 53                 nTT,TT                                                  95.80%      9               ([@b14-ol-0-0-10088])
  Krämer         Germany Austria   2010   221       DTC         P                                                     6.3                 47.7               TT                                                      all         8               ([@b21-ol-0-0-10088])
  Ito            Japan             2010   2,638     PTC         R                                                     7.6                 51.1               TT, sTT, lobectomy                                      0.10%       8               ([@b17-ol-0-0-10088])
  Nixon          USA               2011   707       DTC         R                                                     8.2                 No detail          TT,sTT, lobectomy                                       26%         7               ([@b22-ol-0-0-10088])
  Ibrahimpasic   USA               2012   200       PTC         R                                                     5.2                 No detail          TT                                                      40.1%       8               ([@b23-ol-0-0-10088])
  Avram          USA               2013   116       DTC         R                                                     None                47                 TT, lobectomy                                           3.40%       9               ([@b24-ol-0-0-10088])
  Momesso        Brazil            2014   176       DTC         R                                                     14.1                40.2               TT+sTT                                                  57.3%       9               ([@b26-ol-0-0-10088])
  Han            Korea             2014   176       DTC         R                                                     7.2                 50.1               TT                                                      all         8               ([@b27-ol-0-0-10088])
  Wang           USA               2014   1,522     DTC         R                                                     3.8                 48                 TT,sTT, lobectomy                                       6%          9               ([@b13-ol-0-0-10088])
  Smith          England           2015   35        PTC         R                                                     6                   No detail          TT, lobectomy                                           51.40%      6               ([@b25-ol-0-0-10088])
  Baek           Korea             2015   659       PTC         R                                                     None                45.9               TT,sTT, lobectomy                                       No detail   9               ([@b28-ol-0-0-10088])
  Nilubol        USA               2015   30,184    PTC         R                                                     4.5                 No detail          TT,sTT, lobectomy                                       47.10%      8               ([@b5-ol-0-0-10088])
  Vrachimis      Germany           2015   221       DTC         R                                                     7.8                 47,7               TT                                                      all         8               ([@b6-ol-0-0-10088])
  Chereau        France            2016   2,518     PTC         R                                                     6.5                 50                 TT, lobectomy                                           49.60%      9               ([@b12-ol-0-0-10088])
  Anderson       USA               2016   149,912   DTC         R                                                     None                50.6               TT, lobectomy                                           37.60%      9               ([@b7-ol-0-0-10088])
  Sun            China             2017   269       DTC         R                                                     None                No detail          TT,lobectomy                                            No detail   7               ([@b29-ol-0-0-10088])
  Aydin Buyruk   Turkey            2017   354       PTC         R                                                     None                No detail          TT                                                      No detail   8               ([@b30-ol-0-0-10088])

Study design

surgery; P, prospective study; R, respective study; TT, total thyroidectomy; sTT, subtotal thyroidectomy; nTT, near total thyroidectomy.

###### 

Subgroup analysis of association between tumor size and prognosis.

  Factor   Standard        No.   Q-value   P-value   I^2^   OR      95% CI
  -------- --------------- ----- --------- --------- ------ ------- --------------
  Year       Before 2009   2     0.13      0.014     0.0%   0.800   0.670--0.955
           After 2009      9     4.33      0.000     0.0%   1.498   1.357--1.653

No., the number of articles included; CI, confidence interval; OR, odds ratio.
